Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance, it is the third most common cause of cancer-related mortality worldwide. In the last years the multikinase inhibitor sorafenib has been used for advanced HCC, but some patients do not benefit from this therapy; thus, novel therapeutic options based on molecular approaches are urgently needed. microRNAs are short non coding RNAs involved in several physiological and pathological conditions including HCC and increasing evidence describes miRs as good tools for the molecular targeted therapies in HCC. The purpose of this study was to identify novel approaches to sensitize the HCC cells to sorafenib by microRNAs targeting urokinase-type plasminogen activator (uPA).

Methods

The miR-193a wa

SUBMITTER: Salvi A 

PROVIDER: S-EPMC4029516 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature